Journal Article

Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study

Sasaki, Jun, Oikawa, Shinichi, Tanimura-Inagaki, Kyoko, Nagao, Mototsugu, Sugihara, Hitoshi, Sakuma, Ichiro

2024

Overview

Background SGLT2 inhibitors and DPP4 inhibitors have been suggested to affect lipid metabolism. However, there are few randomized controlled trials comparing the effects on the lipid metabolism between the two types of antidiabetic drugs. The SUCRE study (UMIN ID: 000018084) was designed to compare the effects of ipragliflozin and sitagliptin on serum lipid and apolipoprotein profiles and other clinical parameters. Methods This is a multicenter, open-label, randomized, controlled trial. Patients with type 2 diabetes (20–74 years old) with HbA1c levels of 7.0-10.5% and serum triglyceride levels of 120–399 mg/dL (1.35–4.50 mmol/L) on diet and/or oral hypoglycemic agents were enrolled. Subjects were randomized to treatment with ipragliflozin (50 mg/day, n  = 77) or sitagliptin (50 mg/day, n  = 83). Laboratory measurements were performed at 0, 1, 3, and 6 months of treatment. Results Ipragliflozin and sitagliptin reduced fasting plasma glucose, glycoalbumin, and HbA1c almost equally. Ipragliflozin increased HDL-C and decreased apo E. Sitagliptin decreased TG, apo B48, CII, and CIII, but increased LDL-C. The between-treatment differences were significant for HDL-C ( P  = 0.02) and apo B48 ( P  = 0.006), and nearly significant for apo A1 ( P  = 0.06). In addition, ipragliflozin reduced body weight, blood pressure, serum liver enzymes, uric acid, and leptin, and increased serum ketones compared with sitagliptin. Conclusions While ipragliflozin and sitagliptin showed similar effects on glycemic parameters, the effects on serum lipid and apolipoprotein profiles were different. Ipragliflozin may have an anti-atherogenic effect through modulation of HDL-C and apo E compared to sitagliptin through TG and apo B48, CII, and CIII in patients with type 2 diabetes.

• Publisher: BioMed Central,Springer Nature B.V,BMC
• Subject: Angiology / Antidiabetics / Apolipoproteins / Atherosclerosis / Blood pressure / Body weight / Cardiology / Cardiovascular disease / Cholesterol / Clinical outcomes / Clinical trials / Diabetes / Diabetes mellitus (non-insulin dependent) / Drug dosages / Enzymes / Glucose / Heart failure / High density lipoprotein / Hyperglycemia / Hypoglycemic agents / Immunoassay / Insulin / Laboratories / Leptin / Lipid metabolism / Lipids / Low density lipoprotein / Medicine / Medicine & Public Health / Metabolism / Normal distribution / Patients / Physicians / Triglycerides / Uric acid / Variables